Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Acute therapies continue to report strong growth compared to chronic ones.
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Subscribe To Our Newsletter & Stay Updated
